Antiviral propierties of 5,5'-dithiobis-2-nitrobenzoic acid and bacitracin against T-tropic human immunodeficiency virus type 1
Bacitracin and the membrane-impermeant thiol reagent 5,5’-dithiobis-2-nitrobenzoic acid (DTNB) are agents known to inhibit protein disulfide isomerase (PDI), a cell-surface protein critical in HIV-1 entry therefore they are fusion inhibitors (FI). Here we investigated the possibility that Bacitracin...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Spanish / Castilian |
| Published: |
2011
|
| Online Access: | http://eprints.uanl.mx/15072/1/709.pdf |
| _version_ | 1824414247683096576 |
|---|---|
| author | Lara Villegas, Humberto Herman Ixtepan Turrent, Liliana del Carmen Garza Treviño, Elsa Nancy Flores Teviño, Samantha M. Borkow, Gadi Rodríguez Padilla, Cristina |
| author_facet | Lara Villegas, Humberto Herman Ixtepan Turrent, Liliana del Carmen Garza Treviño, Elsa Nancy Flores Teviño, Samantha M. Borkow, Gadi Rodríguez Padilla, Cristina |
| author_sort | Lara Villegas, Humberto Herman |
| collection | Repositorio Institucional |
| description | Bacitracin and the membrane-impermeant thiol reagent 5,5’-dithiobis-2-nitrobenzoic acid (DTNB) are agents known to inhibit protein disulfide isomerase (PDI), a cell-surface protein critical in HIV-1 entry therefore they are fusion inhibitors (FI). Here we investigated the possibility that Bacitracin and or DTNB might have other antiviral activities besides FI. By means of residual activity assays, we found that both compounds showed antiviral activity only to viruses T-tropic HIV-1 strain. Cell-based fusion assays showed inhibition on HeLa-CD4-LTR-b-gal (CD4) and HL2/3 cells treated with Bacitracin, and DTNB with the latest compound we observed fusion inhibition on both cells but strikingly in HL2/3 cells (expressing Env) indicating a possible activity on both, the cell membrane and the viral envelope. A time-of-addition experiment showed that both compounds act on HIV entry inhibition but DTNB also acts at late stages of the viral cycle. Lastly, we also found evidence of long-lasting host cell protection in vitro by DTNB, an important pharmacodynamic parameter for a topical microbicide against virus infection, hours after the extracellular drug was removed; this protection was not rendered by Bacitracin. These drugs proved to be leading compounds for further studies against HIV showing antiviral characteristics of interest |
| format | Article |
| id | eprints-15072 |
| institution | UANL |
| language | Spanish / Castilian |
| publishDate | 2011 |
| record_format | eprints |
| spelling | eprints-150722024-12-11T15:26:46Z http://eprints.uanl.mx/15072/ Antiviral propierties of 5,5'-dithiobis-2-nitrobenzoic acid and bacitracin against T-tropic human immunodeficiency virus type 1 Lara Villegas, Humberto Herman Ixtepan Turrent, Liliana del Carmen Garza Treviño, Elsa Nancy Flores Teviño, Samantha M. Borkow, Gadi Rodríguez Padilla, Cristina Bacitracin and the membrane-impermeant thiol reagent 5,5’-dithiobis-2-nitrobenzoic acid (DTNB) are agents known to inhibit protein disulfide isomerase (PDI), a cell-surface protein critical in HIV-1 entry therefore they are fusion inhibitors (FI). Here we investigated the possibility that Bacitracin and or DTNB might have other antiviral activities besides FI. By means of residual activity assays, we found that both compounds showed antiviral activity only to viruses T-tropic HIV-1 strain. Cell-based fusion assays showed inhibition on HeLa-CD4-LTR-b-gal (CD4) and HL2/3 cells treated with Bacitracin, and DTNB with the latest compound we observed fusion inhibition on both cells but strikingly in HL2/3 cells (expressing Env) indicating a possible activity on both, the cell membrane and the viral envelope. A time-of-addition experiment showed that both compounds act on HIV entry inhibition but DTNB also acts at late stages of the viral cycle. Lastly, we also found evidence of long-lasting host cell protection in vitro by DTNB, an important pharmacodynamic parameter for a topical microbicide against virus infection, hours after the extracellular drug was removed; this protection was not rendered by Bacitracin. These drugs proved to be leading compounds for further studies against HIV showing antiviral characteristics of interest 2011 Article PeerReviewed text es cc_by_nc_nd http://eprints.uanl.mx/15072/1/709.pdf http://eprints.uanl.mx/15072/1.haspreviewThumbnailVersion/709.pdf Lara Villegas, Humberto Herman y Ixtepan Turrent, Liliana del Carmen y Garza Treviño, Elsa Nancy y Flores Teviño, Samantha M. y Borkow, Gadi y Rodríguez Padilla, Cristina (2011) Antiviral propierties of 5,5'-dithiobis-2-nitrobenzoic acid and bacitracin against T-tropic human immunodeficiency virus type 1. Virology journal, 8 (1). pp. 1-8. ISSN 1743-422X http://doi.org/10.1186/1743-422X-8-137 doi:10.1186/1743-422X-8-137 |
| spellingShingle | Lara Villegas, Humberto Herman Ixtepan Turrent, Liliana del Carmen Garza Treviño, Elsa Nancy Flores Teviño, Samantha M. Borkow, Gadi Rodríguez Padilla, Cristina Antiviral propierties of 5,5'-dithiobis-2-nitrobenzoic acid and bacitracin against T-tropic human immunodeficiency virus type 1 |
| thumbnail | https://rediab.uanl.mx/themes/sandal5/images/online.png |
| title | Antiviral propierties of 5,5'-dithiobis-2-nitrobenzoic acid and bacitracin against T-tropic human immunodeficiency virus type 1 |
| title_full | Antiviral propierties of 5,5'-dithiobis-2-nitrobenzoic acid and bacitracin against T-tropic human immunodeficiency virus type 1 |
| title_fullStr | Antiviral propierties of 5,5'-dithiobis-2-nitrobenzoic acid and bacitracin against T-tropic human immunodeficiency virus type 1 |
| title_full_unstemmed | Antiviral propierties of 5,5'-dithiobis-2-nitrobenzoic acid and bacitracin against T-tropic human immunodeficiency virus type 1 |
| title_short | Antiviral propierties of 5,5'-dithiobis-2-nitrobenzoic acid and bacitracin against T-tropic human immunodeficiency virus type 1 |
| title_sort | antiviral propierties of 5 5 dithiobis 2 nitrobenzoic acid and bacitracin against t tropic human immunodeficiency virus type 1 |
| url | http://eprints.uanl.mx/15072/1/709.pdf |
| work_keys_str_mv | AT laravillegashumbertoherman antiviralpropiertiesof55dithiobis2nitrobenzoicacidandbacitracinagainstttropichumanimmunodeficiencyvirustype1 AT ixtepanturrentlilianadelcarmen antiviralpropiertiesof55dithiobis2nitrobenzoicacidandbacitracinagainstttropichumanimmunodeficiencyvirustype1 AT garzatrevinoelsanancy antiviralpropiertiesof55dithiobis2nitrobenzoicacidandbacitracinagainstttropichumanimmunodeficiencyvirustype1 AT florestevinosamantham antiviralpropiertiesof55dithiobis2nitrobenzoicacidandbacitracinagainstttropichumanimmunodeficiencyvirustype1 AT borkowgadi antiviralpropiertiesof55dithiobis2nitrobenzoicacidandbacitracinagainstttropichumanimmunodeficiencyvirustype1 AT rodriguezpadillacristina antiviralpropiertiesof55dithiobis2nitrobenzoicacidandbacitracinagainstttropichumanimmunodeficiencyvirustype1 |